Helocyte, Inc., a subsidiary of Fortress Biotech, Inc., is a New York-based company dedicated to the advancement and distribution of innovative immunotherapies targeting cancer and infectious diseases, with a particular focus on cytomegalovirus (CMV). Their pipeline includes the development of the CMV Triplex ConVax, and their mission is to provide effective prevention and treatment options for these challenging medical conditions.
With a strong management team and scientific advisory board, Helocyte, Inc. is committed to driving scientific research and development in the field of immunotherapy. Their dedication to finding novel solutions and their focus on commercialization make them a key player in the fight against cancer and infectious diseases.
Generated from the website